microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C

Liver International

Volumn 36, Issue 3, 2016, Pages 334-343

  Van Keuren Jensen, Kendall R ^a   Malenica, Ivana ^a   Courtright, Amanda L ^a   Ghaffari, Layla T ^a   Starr, Alex P ^a   Metpally, Raghu P ^a   Beecroft, Taylor A ^a   Carlson, Elizabeth W J ^a   Kiefer, Jeffrey A ^a   Pockros, Paul J ^b   Rakela, Jorge ^c  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b Division of Gastroenterology and Hepatology   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Fibrosis; Hepatitis C; Liver; MicroRNA; Sequencing

Indexed keywords

MICRORNA; MICRORNA 182; MIR 122 3P; MIR 1260B; MIR 148 5P; MIR 183; MIR 200A 5P; MIR 378I; MIR199A 5P; UNCLASSIFIED DRUG; GENETIC MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; MIDDLE AGED; MOLECULAR MECHANICS; NEXT GENERATION SEQUENCING; RNA SEQUENCE; UPREGULATION; BIOPSY; CHEMISTRY; COMPLICATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC MARKER; GENETICS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; SEQUENCE ANALYSIS; TIME FACTOR; VIROLOGY;

AGED; BIOPSY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC MARKERS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEQUENCE ANALYSIS, RNA; TIME FACTORS;

EID: 84958979975     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12919     Document Type: Article

References (62)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
2. Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002; 17: 423-30.
3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47-52.
4. Lee JE, Yi R. Highly efficient ligation of small RNA molecules for microRNA quantitation by high-throughput sequencing. J Vis Exp 2014; 18: e52095.
5. Wojcicka A, Swierniak M, Kornasiewicz O, et al. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. Int J Biochem Cell Biol 2014; 53: 208-17.
6. Murakami Y, Toyoda H, Tanaka M, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011; 6: e16081.
7. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937.
8. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013; 5: 479-86.
9. Li J, Fu H, Xu C, et al. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 2010; 10: 354.
10. Goeppert B, Schmezer P, Dutruel C, et al. Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology 2010; 52: 2023-33.
11. Liang Z, Gao Y, Shi W, et al. Expression and significance of microRNA-183 in hepatocellular carcinoma. ScientificWorldJournal 2013; 2013: 381874.
12. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
13. Burgos KL, Javaherian A, Bomprezzi R, et al. Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA 2013; 19: 712-22.
14. Stocks MB, Moxon S, Mapleson D, et al. The UEA sRNA workbench: a suite of tools for analysing and visualizing next generation sequencing microRNA and small RNA datasets. Bioinformatics 2012; 28: 2059-61.
15. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biology 2010; 11: R106. doi:10.1186/gb-2010-11-10-r106.
16. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2010. Retrieved from http://www.r-project.org.
17. Wang M, Wang Y, Zang W, et al. Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells. Tumour Biol 2014; 35: 39-46.
18. Qin J, Luo M, Qian H, Chen W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene 2014; 538: 342-7.
19. Wang J, Li J, Shen J, et al. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012; 12: 227.
20. Huynh C, Segura MF, Gaziel-Sovran A, et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011; 30: 1481-8.
21. Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2012; 18: 5442-53.
22. Wang C, Ren R, Hu H, et al. MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chin J Cancer Res 2014; 26: 17-29.
23. Dolganiuc A, Petrasek J, Kodys K, et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 2009; 33: 1704-10.
24. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-45.
25. Li J, Shi W, Gao Y, et al. Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. Clin Lab 2013; 59: 1009-15.
26. Wang Y, Gao Y, Shi W, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark 2014; 15: 171-80.
27. Feng YY, Xu XQ, Ji CB, et al. Aberrant hepatic microRNA Expression in nonalcoholic fatty liver disease. Cell Physiol Biochem 2014; 34: 1983-97.
28. Liu J, Ruan B, You N, et al. Downregulation of miR-200a induces EMT phenotypes and CSC-like signatures through targeting the beta-catenin pathway in hepatic oval cells. PLoS One 2013; 8: e79409.
29. Sun X, He Y, Ma TT, et al. Participation of miR-200a in TGF-beta1-mediated hepatic stellate cell activation. Mol Cell Biochem 2014; 388: 11-23.
30. Yuan JH, Yang F, Chen BF, et al. The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 2011; 54: 2025-35.
31. Chiu LY, Kishnani PS, Chuang TP, et al. Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. J Gastroenterol 2014; 49: 1274-84.
32. Dhayat SA, Mardin WA, Kohler G, et al. The microRNA-200 family-a potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol 2014; 110: 430-8.
33. Petrelli A, Perra A, Cora D, et al. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology 2014; 59: 228-41.
34. Benoit C, Ould-Hamouda H, Crepin D, et al. Early leptin blockade predisposes fat-fed rats to overweight and modifies hypothalamic microRNAs. J Endocrinol 2013; 218: 35-47.
35. Alisi A, Da Sacco L, Bruscalupi G, et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 2011; 91: 283-93.
36. Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol 2013; 20(Suppl 3): S360-8.
37. Yang YM, Lee WH, Lee CG, et al. Galpha gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma. Oncogene 2014; 34: 2910-21.
38. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009; 50: 453-60.
39. Yang J, Han S, Huang W, et al. A meta-analysis of microRNA expression in liver cancer. PLoS One 2014; 9: e114533.
40. Cardin R, Piciocchi M, Sinigaglia A, et al. Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. BMC Cancer 2012; 12: 177.
41. Jia XQ, Cheng HQ, Qian X, et al. Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma. Cell Biochem Biophys 2012; 62: 237-44.
42. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-60.
43. Shen Q, Cicinnati VR, Zhang X, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer 2010; 9: 227.
44. Zhang J, Zhang D, Wu GQ, Feng ZY, Zhu SM. Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. Hepatobiliary Pancreat Dis Int 2013; 12: 305-9.
45. Dai BH, Geng L, Wang Y, et al. microRNA-199a-5p protects hepatocytes from bile acid-induced sustained endoplasmic reticulum stress. Cell Death Dis 2013; 4: e604.
46. Kanda T, Ishibashi O, Kawahigashi Y, et al. Identification of obstructive jaundice-related microRNAs in mouse liver. Hepatogastroenterology 2010; 57: 1013-23.
47. Ogawa T, Enomoto M, Fujii H, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012; 61: 1600-9.
48. Mobus S, Yang D, Yuan Q, et al. MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. J Hepatol 2014; 62: 101-10.
49. Xu N, Zhang J, Shen C, et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 2012; 423: 826-31.
50. Pan L, Huang S, He R, et al. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res 2014; 19: 68.
51. He XX, Kuang SZ, Liao JZ, et al. The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma. Mol BioSyst 2014; 11: 532-9.
52. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51: 881-90.
53. Heo MJ, Kim YM, Koo JH, et al. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget 2014; 5: 2792-806.
54. Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol 2014; 31: 984.
55. Yan H, Dong X, Zhong X, et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog 2014; 53: 960-9.
56. Gailhouste L, Gomez-Santos L, Hagiwara K, et al. miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology 2013; 58: 1153-65.
57. Han H, Sun D, Li W, et al. A c-Myc-MicroRNA functional feedback loop affects hepatocarcinogenesis. Hepatology 2013; 57: 2378-89.
58. Li L, Liu Y, Guo Y, et al. Regulatory miR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology 2014; 61: 574-84.
59. Rieger JK, Klein K, Winter S, Zanger UM. Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association with gene expression. Drug Metab Dispos 2013; 41: 1752-62.
60. Xu X, Fan Z, Kang L, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 2013; 123: 630-45.
61. Farid WR, Pan Q, van der Meer AJ, et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 2012; 18: 290-7.
62. Magrelli A, Azzalin G, Salvatore M, et al. Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol 2009; 2: 157-63.